PTPN6 and serum lipopolysaccharide activity: Our data further suggest that the development of anti- endotoxemia therapy concurring to induce SHP-1 activity could represent a new avenue to consider, as actual therapies mainly focusing at specifically blocking TNF-α and other pro-inflammatory cytokines showed limited successes.